Neutrophil role in in vivo anti-lymphoma activity of rituximab:: FCGR3B-NA1/NA2 polymorphism does not influence response and survival after rituximab treatment

被引：16

作者：

Cartron, G. ^{[1
,2
,3
]}

Ohresser, M. ^{[1
]}

Salles, G. ^{[4
]}

Solal-Celigny, P. ^{[5
]}

Colombat, P. ^{[6
]}

Watier, H. ^{[1
]}

机构：

[1] Univ Tours, EA3853, Tours, France

[2] CHU Lapeyronie, INSERM, U847, Montpellier, France

[3] CHU Lapeyronie, Serv Hematol & Biotherapies, Montpellier, France

[4] Univ Lyon 1, Hosp Civiles Lyon, Serv Hematol, Lyon, France

[5] Ctr Jean Bernard, Dept Hematol, Le Mans, France

[6] CHU Bretonneau, Serv Hematol & Therapie Cellulaire, Tours, France

来源：

ANNALS OF ONCOLOGY | 2008年 / 19卷 / 08期

关键词：

Fc gamma RIIIb; follicular lymphoma; neutrophils; rituximab;

D O I：

10.1093/annonc/mdn163

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background: Neutrophils could play an important role in in vivo rituximab anti-lymphoma activity. Fc gamma RIIIb is expressed only by neutrophils and Fc gamma RIIIb-neutrophil antigen (NA)1/NA2 polymorphism influenced phagocytosis of immunoglobulin G1-opsonized particles. We formulated the hypothesis that if neutrophils are critical cells for in vivo rituximab activity, Fc gamma RIIIb-NA1/NA2 polymorphism could influence the response to rituximab. Patients and methods: FCGR3B-NA1/NA2 genotypes were determined in 46 patients having received rituximab for a previously untreated, follicular, non-Hodgkin's lymphoma. The clinical response and the disappearance of the BCL2-JH gene rearrangement in both peripheral blood and bone marrow were evaluated at 2 months (M2) and each year during 7 years. Results: They were 13% homozygous for FCGR3B-NA1, 61% homozygous for FCGR3B-NA1/NA2 and 26% heterozygous. The objective response rates at M2 were 67% in homozygous FCGR3B-NA1 patients compared with 75% in homozygous FCGR3B-NA2 and 75% in heterozygous patients (not significant). We found no difference for progression-free and overall survival by FCGR3B-NA1/NA2 genotypes. Conclusion: These results indicate no association between FCGR3B-NA1/NA2 polymorphism and response to rituximab indicating no significant role of phagocytosis mediated by neutrophils in in vivo mechanism of rituximab activity.

引用

页码：1485 / 1487

页数：3

共 19 条

[1]

BREDIUS RGM, 1994, IMMUNOLOGY, V83, P624

[2] NA GENE-FREQUENCIES IN THE GERMAN POPULATION, DETERMINED BY POLYMERASE CHAIN-REACTION WITH SEQUENCE-SPECIFIC PRIMERS [J].

BUX, J ;

STEIN, EL ;

SANTOSO, S ;

MUELLERECKHARDT, C .

TRANSFUSION, 1995, 35 (01) :54-57

[3] From the bench to the bedside: ways to improve rituximab efficacy [J].

Cartron, G ;

Watier, H ;

Golay, J ;

Solal-Celigny, P .

BLOOD, 2004, 104 (09) :2635-2642

[4] Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcγRIIIa gene [J].

Cartron, G ;

Dacheux, L ;

Salles, G ;

Solal-Celigny, P ;

Bardos, P ;

Colombat, P ;

Watier, H .

BLOOD, 2002, 99 (03) :754-758

[5] Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden:: clinical and molecular evaluation [J].

Colombat, P ;

Salles, G ;

Brousse, N ;

Eftekhari, P ;

Soubeyran, P ;

Delwail, V ;

Deconinck, E ;

Haïoun, C ;

Foussard, C ;

Sebban, C ;

Stamatoullas, A ;

Milpied, N ;

Boué, F ;

Taillan, B ;

Lederlin, P ;

Najman, A ;

Thièblemont, C ;

Montestruc, F ;

Mathieu-Boué, A ;

Benzohra, A ;

Solal-Céligny, P .

BLOOD, 2001, 97 (01) :101-106

[6]

Colombat P, 2006, BLOOD, V108, p147A

[7] The IgG Fc receptor family [J].

Gessner, JE ;

Heiken, H ;

Tamm, A ;

Schmidt, RE .

ANNALS OF HEMATOLOGY, 1998, 76 (06) :231-248

[8] Concurrent administration of granulocyte colony-stimulating factor or granulocyte-monocyte colony-stimulating factor enhances the biological activity of rituximab in a severe combined immunodeficiency mouse lymphoma model [J].

Hernandez-Ilizaliturri, FJ ;

Jupudy, V ;

Reising, S ;

Repasky, EA ;

Czuczman, MS .

LEUKEMIA & LYMPHOMA, 2005, 46 (12) :1775-1784

[9]

Hernandez-Ilizaliturri FJ, 2003, CLIN CANCER RES, V9, P5866

[10] Relevance, advantages and limitations of animal models used in the development of monoclonal antibodies for cancer treatment [J].

Loisel, Severine ;

Ohresser, Marc ;

Pallardy, Marc ;

Dayde, David ;

Berthou, Christian ;

Cartron, Guillaume ;

Watier, Herve .

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2007, 62 (01) :34-42

← 1 2 →